| Title |
Psychostimulants in the Treatment of Depression
|
|---|---|
| Published in |
CNS Drugs, August 2012
|
| DOI | 10.2165/00023210-200721030-00004 |
| Pubmed ID | |
| Authors |
Katy Orr, David Taylor |
| Abstract |
Psychostimulants have euphoric and alerting properties that suggest their usefulness in treating depressive disorders; however, problems with tolerance and dependence with some drugs militate against their widespread therapeutic use where more acceptable licensed alternatives are available. The introduction of modafinil, a stimulant not associated with tolerance and dependence, has re-awakened interest in psychostimulants as antidepressants. The available literature, while containing somewhat inconsistent data of rather poor quality, does suggest that psychostimulants have useful antidepressant properties and are usually well tolerated. They may be useful as adjuncts to standard antidepressants in refractory depression, but have particular utility in conditions where a prompt therapeutic effect is desired and where tolerance and dependence are less of a concern. Such conditions include the treatment of depression in terminal illness and in extreme old age.Psychostimulants, although now largely discarded as treatment options for depression, deserve careful consideration as potential therapeutic agents in specific patient subgroups. |
Mendeley readers
The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 2 | 3% |
| United States | 2 | 3% |
| Unknown | 65 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 20% |
| Student > Bachelor | 10 | 14% |
| Other | 6 | 9% |
| Student > Ph. D. Student | 6 | 9% |
| Professor > Associate Professor | 5 | 7% |
| Other | 14 | 20% |
| Unknown | 14 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 46% |
| Psychology | 10 | 14% |
| Agricultural and Biological Sciences | 3 | 4% |
| Philosophy | 2 | 3% |
| Social Sciences | 2 | 3% |
| Other | 6 | 9% |
| Unknown | 14 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 August 2017.
All research outputs
#8,535,472
of 25,374,917 outputs
Outputs from CNS Drugs
#768
of 1,388 outputs
Outputs of similar age
#64,270
of 187,955 outputs
Outputs of similar age from CNS Drugs
#275
of 541 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,388 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.6. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 187,955 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 541 others from the same source and published within six weeks on either side of this one. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.